Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma

Topics

Hepatocellular carcinoma · locally advanced hepatocellular carcinoma · Stereotactic body radiotherapy · sorafenib · Macrovascular invasion · Overall survival · Progression-free survival · phase 3 randomized clinical trial · First-line treatment · liver function · Locoregional therapy · Stereotactic body radiotherapy · Treatment-related adverse events · Quality of life · hazard ratio · Liver failure · Performance status · Metastatic tumors · Multicenter study · Radiotherapy fractionation · Systemic therapy · early trial termination · standard-of-care systemic therapy · Grade 3 or higher adverse events · stratification factors · Combination therapy